Skip to main content
. 2021 Sep 28;13(19):4855. doi: 10.3390/cancers13194855

Figure 4.

Figure 4

HSP27 regulates NFκB activity and IAP expression. (A) Western blot of the phosphorylated (active) NFκB, cIAP1 (BIRC2), and cIAP2 (BIRC3) in cisplatin-stimulated A2780CIS cells treated either with the vehicle (Veh) or 1.5 µM ivermectin (IVM) treatments. (B) Western blot of the phosphorylated (active) NFκB, cIAP1 (BIRC2), and cIAP2 (BIRC3) in cisplatin-treated A2780CIS-scrm and A2780CIS-shHSP27 #1 and #2 cells. (C) Western blot of phosphorylated (active) NFκB, cIAP1 (BIRC2), and cIAP2 (BIRC3) in cisplatin-treated ES2 cells cultured in the control, COL11A1-positive a-cellular matrix, COL11A1-negative a-cellular matrix, and COL11A1-positive a-cellular matrix plus the 1.5 µM ivermectin (IVM)-treated conditions. (D) Western blot of phosphorylated (active) NFκB, cIAP1 (BIRC2), and cIAP2 (BIRC3) in cisplatin-treated A2780-scrm and A2780-shHSP27 #1 and #2 cells cultured on COL11A1. GAPDH was used as a loading control for the Western blots. All experiments were performed in the standard experiment conditions (cells cultured in the above conditions for 3 days in 1% FBS medium after overnight serum starvation). The uncropped Western blot figures are presented in Figure S8.